HypoPARAthyroidism Association
Non-Profit & Charitable Organizations · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1650 Double Falls Dr, Frisco, Texas, 750...Website
www.hypopara.orgRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About HypoPARAthyroidism Association
HypoPARAthyroidism Association, Inc. is a non-profit organization dedicated to improving the lives of individuals affected by hypoPARAthyroidism through education, support, research, and advocacy. The organization aims to raise awareness about this rare endocrine disorder, which is characterized by low calcium levels and low or absent parathyroid hormone. They provide resources such as patient stories, recommended doctors, and information on clinical trials. Their intended clients include patients with hypoPARAthyroidism, their families, and the broader community seeking support and information.Explore more
HypoPARAthyroidism Association Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HypoPARAthyroidism Association your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if HypoPARAthyroidism Association had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on HypoPARAthyroidism Association recently announced quarterly report
Check out if HypoPARAthyroidism Association is spiking on competitors!
Product Launch: Get notified when HypoPARAthyroidism Association launches new products
Congratulate Masked Content for being promoted to Masked Content at HypoPARAthyroidism Association
Website visits: Recent activity has been detected on your website
HypoPARAthyroidism Association, which may be a good buyer, showed buying intent in Masked Content Topic
Check if HypoPARAthyroidism Association has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once HypoPARAthyroidism Association has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to HypoPARAthyroidism Association
Compare insights from companies similar to HypoPARAthyroidism Association, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
HypoPARAthyroidism Association is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
HypoPARAthyroidism Association is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about HypoPARAthyroidism Association.
HypoPARAthyroidism Association Tech Stack
A closer look at the technologies used by HypoPARAthyroidism Association
HypoPARAthyroidism Association News & Media
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of ...
Financing led by Wellington Management with participation from other leading healthcare fundsCARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the closing of a $115 million Series B financing. The Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture ParMBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
MBX 2109 is in clinical development for treatment of hypoparathyroidism MBX 2109 is in clinical development for treatment of hypoparathyroidismMBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing precision endocrine peptide therapeutics to treat endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to its lead therapeutic product candidate, MBX 2109, for the treatment of hypoparathyroidism.HypoPARAthyroidism Association Launches the First-of-its-Kind Patient-Powered Data Platform to Advance Patient Care
Hypoparathyroidism affects an estimated 100,000 people in the United States, and there are currently no widely available FDA-approved treatment options to address the underlying disease
Read more news
Top Non-Profit & Charitable Organizations Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HypoPARAthyroidism Association
Sign Up For FreeTo access detailed company insights
HypoPARAthyroidism Association, Inc. is a non-profit organization dedicated to improving the lives of individuals affected by hypoPARAthyroidism through education, support, research, and advocacy. The organization aims to raise awareness about this rare endocrine disorder, which is characterized by low calcium levels and low or absent parathyroid h... Read More
